Goldman initiated coverage on Immunovant Sciences with a new price target

3/13/24 7:36:35 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Goldman initiated coverage of Immunovant Sciences with a rating of Buy and set a new price target of $50.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMVT

Date	Price Target	Rating	Analyst
3/3/2025	$20.00	Hold	Jefferies
1/3/2025		Outperform → Peer Perform	Wolfe Research
10/10/2024	$36.00	Outperform	Raymond James
10/9/2024	$47.00 → $53.00	Outperform	Oppenheimer
3/28/2024	$50.00	Outperform	Oppenheimer
3/13/2024	$50.00	Buy	Goldman
2/20/2024	$51.00	Overweight	JP Morgan
2/15/2024	$55.00	Outperform	Wolfe Research